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Abstract
Purpose Patients with differentiated thyroid cancer (DTC) typically have a favourable prognosis and recurrence as late as 45
years after diagnosis has been reported. International clinical guidelines for monitoring recommend routine thyroglobulin,
ultrasound and physical examination for the detection of recurrence. The aim of this review was to systematically review
whether routine monitoring using thyroglobulin (Tg), neck ultrasound and physical examination for recurrence in differ-
entiated thyroid cancer patients is effective in improving patient survival and/or quality of life.
Methods Primary studies were retrieved via a comprehensive search of three electronic bibliographic databases (PubMed,
Web of Science Core Collection and Cochrane Library) without time restriction. Eligible studies must have reported on
disease-free patients with DTC subject to long-term routine surveillance. The primary and secondary outcomes of interest
were overall survival (or other survival parameters) and quality of life, respectively.
Results Literature searches yielded 5529 citations, which were screened by two reviewers. 241 full texts were retrieved. No
randomised controlled trials or two-arm cohort studies on the effectiveness of any of the three speciﬁed interventions were
identiﬁed. However, three ‘single-arm’ studies reporting long-term follow-up outcomes in patients undergoing regular
surveillance were identiﬁed and appraised.
Conclusions This review highlights a lack of empirical evidence to support current use of routine surveillance in DTC.
Although early detection is possible, routine surveillance may lead to unnecessary intervention.
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Introduction
The vast majority of thyroid malignancy is differentiated
thyroid cancer (DTC), originating from thyroid follicular
epithelium. DTC is comprised of papillary thyroid cancer
(PTC) in 85–90% of instances and follicular thyroid cancer
(FTC) in 5–10% [1]. The incidence of thyroid cancer has
risen over the past few decades, largely driven by an
increase in PTC [2]. An associated decrease in mortality
rates [3] suggests that clinically insigniﬁcant PTC is
increasingly being identiﬁed.
DTC is usually indolent and often found incidentally [4].
The overall prognosis at 10 years is 90–95%. Patients who
are disease free following treatment have a life expectancy
similar to the general population [4, 5]. However, 5–20% of
patients develop local recurrence and over 10% develop
distant metastases; the risk increasing with age at diagnosis
[6]. Up to two-thirds of relapses can be detected within the
ﬁrst decade by serum thyroglobulin (Tg) and imaging, but
some relapses are observed as late as 45 years [7, 8]. The
late recurrences reported in earlier studies may be inﬂu-
enced by follow-up protocols used in these populations that
may be different to current regimes in terms of imaging
modalities used and length of follow up; but this data has
been used as the basis for current practice in several
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countries to routinely monitor patients for life. Clinical
guidelines produced by the American Thyroid Association
(ATA), the British Thyroid Association (BTA) and the
European Society of Medical Oncology (ESMO) [6, 9, 10]
recommend differing regimes involving routine measure-
ments of serum Tg, neck ultrasound (US) and physical
examination (PE) to detect recurrence.
Tg is a dimeric glycoprotein released by normal follicular
tissue and DTC [11]. Tg detection after thyroidectomy
suggests either residual thyroid tissue or persistent or
recurrent cancer [12]. Although recommended as a routine
test for monitoring recurrence in DTC, there are concerns
regarding assay sensitivity and inter-assay variation [9, 13].
False-negatives results may occur due to interference with
anti-Tg antibodies (TgAb) in up to 30% of patients from
saturation and Tg-negative tumours [13–15]. Tg measure-
ment under TSH stimulation enhances test sensitivity [16].
More signiﬁcantly, the trend in serial Tg levels is more
accurate in detecting cancer recurrence [17].
Since the 1960s, US has transformed thyroid cancer
management in the detection of recurrence by guiding
biopsies and mapping disease before surgery [18]. US may
be more sensitive than serum Tg measurements or radio-
iodine whole body scans (WBS) [19]. However, detection
of lesions as small as 2–3 mm has increased detection of
subclinical recurrent disease [20]. At these sizes, US does
not distinguish between residual thyroid tissue and malig-
nant disease [9, 20]. This increases the risk of false-positive
US, unnecessary biopsy and leads to increased anxiety in
patients, particularly in ‘low risk’ disease [18, 21].
PE identiﬁes palpable thyroid nodules in around 90% of
symptomatic DTC patients. However, only 5% of all
patients presenting with thyroid nodules have thyroid can-
cer [10]. For initial diagnosis, clinicians evaluate the
Table 1 The American Thyroid Association (ATA), British Thyroid Association (BTA) and European Society of Medical Oncology (ESMO)
recommendations on routine monitoring of patients with DTC and the ‘self-reported’ basis of these recommendations
ATA Follow-up of low-risk patients should
include PE
⇒ Weak recommendation
⇒ Low-quality evidence
Tg (and TgAb) every 6–24 months dependent
on ‘risk’
⇒ Strong recommendation
⇒ Moderate to low-quality evidence
US every 6–24 months dependent on
‘risk’
⇒ Strong recommendation
⇒ Moderate to low-quality evidence
BTA Follow-up should include PE
⇒ Weak recommendation
⇒ Expert opinion
Tg (and TgAb) no more frequently than
3 monthly
⇒ Weak recommendation
⇒ Expert opinion
No recommendation
ESMO Follow-up should include PE
⇒ No grading of evidence or
recommendation
Tg annually
⇒ No grading of evidence or recommendation
US annually
⇒ No grading of evidence or
recommendation
Table 2 American Thyroid
Association (ATA) and
European Society of Medical
Oncology (ESMO) risk
stratiﬁcation criteria for
differentiated thyroid cancer
ATA [9]
Low risk Intermediate risk High risk
No local/distant metastases Microscopic local invasion Macroscopic invasion
All macroscopic tumour
resected
Cervical LNM OR
Positive post-ablation WBS
outside the thyroid bed
OR
Tumour with aggressive
histology or vascular invasion
Incomplete resection
No local tumour invasion Distant metastases
No aggressive histology or
vascular invasion
Thyroglobulinaemia that is not
proportionate to post-ablative WBS
Negative post-ablation WBS
outside the thyroid bed
ESMO [42]
Very low risk Low risk High risk
Total thyroidectomy No local/distant metastases Less than total thyroidectomy
Unifocal carcinoma less than
1 cm with no ETE or LNM
No local tumour invasion
No aggressive histology or
vascular invasion
Local tumour invasion
Cervical LNM
Distant metastases
Aggressive histology or vascular
invasion
Note: WBS 131I whole body scintigraphy, ETE extra-thyroidal extension, LNM lymph node metastases [40]
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likelihood of malignancy based on consistency, history of
rapid growth and ﬁxity; supported by other features
including voice change, compressive symptoms and palp-
able lymphadenopathy [6]. In the absence of worrying
features on examination and imaging, some palpable lumps
may simply be observed in the pre-diagnosis setting.
However, due to the risk of recurrence, any palpable mass
detected during follow-up of thyroid cancer patients is
treated with suspicion, however, not all recurrences are
palpable. The sensitivity of examination varies with clin-
ician experience and centre volume and is lower than
radioiodine WBS, serum Tg measurements and US scans
[19]. As with US, its utility is limited to the detection of
local recurrence and not distant metastasis.
Given the uncertainties highlighted above, it is unsur-
prising that clinical practice and guidelines from various
organisations vary signiﬁcantly, as shown in Table 1.
Based on the ATA risk stratiﬁcation (Table 2), low-risk
patients may be monitored annually after the initial
6–12 monthly follow-ups and high-risk patients are to be
monitored 6–12 monthly for as long as deemed necessary
[9]. This practice is ‘strongly recommended’, but based on
moderate and low quality evidence; where there was either
‘minor’ or ‘serious’ concern regarding the ‘internal validity
or external generalizability of the results’ [9]. Also, the
guidelines cite studies focussing on the technical aspects of
interventions (i.e. different Tg assay sensitivities, anti-Tg
antibody interference, US criteria for malignancy) and
surrogate outcomes (such as assessing radioiodine ablation
(RIA) success); but not on clinical outcomes such as quality
of life or survival.
The BTA recommends regular PE and Tg no more fre-
quently than three-monthly. Patients who respond well to
therapy are seen every 6–12 months. However, this is based
on ‘expert opinion’ extrapolated from studies with different
primary objectives [6]. The references listed in the guide-
lines to support the recommendations on monitoring focus
primarily on the practicality of Tg [6]. The ESMO recom-
mends annual PE, serum Tg and US for long-term follow-
up [10]. The strength of recommendation and the quality of
supporting evidence are not clear.
Given the apparent lack of good evidence to support
interventions that are currently part of standard care, this
systematic review aimed to determine whether there is
evidence that routine serum Tg measurement, neck US and
PE improve survival and/or quality of life of patients with
DTC.
Methodology
The protocol for this research was registered with the
international register of systematic reviews PROSPERO
(https://www.crd.york.ac.uk/PROSPERO) in March 2017
(ID: 42017060636).
Medical bibliographic databases including PubMed,
Web of Science Core Collection and the Cochrane library
were searched from inception until the 11 April 2017 for
English-language original articles on this topic. Search
terms included thyroid cancer (or neoplasm), recurrence (or
relapse or metastasis), Tg, US (or ultrasonography or
sonography) and PE (or palpation).
The review aimed to include randomised controlled trials
(RTCs) and non-randomised two-cohort interventional or
observational studies evaluating patients undergoing routine
serum Tg, neck US or PE (individually or in combination)
following treatment for DTC. Single-arm studies with no
control group were initially excluded as well as those with
historical controls. Patients with poorly differentiated or
anaplastic thyroid cancer, as well as those diagnosed with
cancer of non-follicular epithelial origin were excluded.
Studies must have compared the speciﬁc ‘follow up’
intervention to a control cohort that have either not under-
gone routine surveillance or have undergone a different
regime of surveillance. The primary outcome to assess
effectiveness was overall survival, measured from diagnosis
to death, or other survival parameters, regardless of the
length of follow-up. The secondary outcome was the quality
of life, measured as deﬁned by the individual studies. The
PRISMA ﬂow diagram depicting the identiﬁcation of stu-
dies for the review is shown in Fig. 1.
Two reviewers (J.G. and G.S.) independently screened
titles and abstracts generated from the searches described (J.
G. and G.S.). Any disagreements were resolved by dis-
cussion and the ﬁnal opinion of the senior author (S.P.B.).
A summary of the effects of interventions and tabulation of
data on demographics, study design, primary and secondary
Articles identified through database searching 
of WOS (n=2610), PubMed (n=4442) and 
Cochrane Library (n=104) 
(n=7156) 
Titles and abstracts screened 
(n= 5529) 
Full texts screened 
(n=241) 
Excluded: 
Not thyroid cancer   (n=887) 
Not differentiated thyroid cancer (n=596) 
Not Tg, US or PE   (n=2202) 
Not follow-up    (n=818) 
Not a primary research article (n=658) 
Not human subjects   (n=20) 
Not in the English language  (n=107)
Duplicates= 1627 
Eligible studies 
 (n=0) 
Excluded: 
Not differentiated thyroid cancer (n=1)  
Wrong intervention   (n=70) 
Wrong population   (n=41) 
Not routine follow-up   (n=30) 
Predictive factors for recurrence (n=45) 
Prognostic factors of tumour  (n=25) 
Not in the English language  (n=3) 
Review     (n=3) 
Single arm cohort   (n=23) 
Fig. 1 PRISMA ﬂowchart demonstrating the reasons for study
exclusion
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Table 3 Eligible single arm retrospective cohort studies
Author Population Risk classiﬁcation and monitoring protocols Frequency of
monitoring
Follow-up period
(average in years)
Survival Detection of recurrence via Tg
Conrad et al.
[23]
343 DTC patients treated with
near-total thyroidectomy
130 ‘low risk’ patients: PE+ Tg Annual 6 (parameter not
stated)
Overall survival
At 10 years: 95%
At 20 years: 93%
6/130 had elevated Tg:
4 true positives (detected by
WBS)
2 false positives
124 true negatives
213 ‘high risk’ patients:
WBS+ Tg+ PE
→ 39/213 showed extra-thyroidal uptake on
WBS and received RIA; 7 had persistent
disease
→ 174/213 had uptake suggestive of remnant
normal tissue, 135 of which still received
RIA;
4 had new extra thyroidal uptake.
WBS at discretion
of physician
19/163 patients with
‘physiological’ uptake on WBS
had elevated Tg:
10 true positives (detected by
WBS)
9 false positives
136 true negatives
8 false negatives (detected by PE)
5/11 patients with ‘persistent’
disease had an elevated Tg.
Lin et al.
[15]
847 DTC patients treated with
total thyroidectomy and ablation
WBS, CXR+Tg
Group A
1 month post-operative Tg < 1 ng/ml
Group B
1 month post-operative 1 < Tg < 10 ng/ml
Group C
1 month post-operative Tg > 10 ng/ml
6 month intervals Group A
3.7 (mean)
Group B
6.1 (mean)
Group C
5.4 (mean)
5-year survival
probability:
Group A 1.00
Group B 0.992
Group C 0.963
2.36% died of
thyroid cancer
Sufﬁcient data not available
Phan et al.
(2002)
346 DTC patients treated with
thyroidectomy and RIA→
94a patients had undetectable Tg
post-ablation with TSH > 30mU/
l.
PE, Tg, TgAb, US+MRIb
→ persistence/recurrence was detected by
imaging modalities such as FDG PET or CT
(or MRI if Tg was undetectable)
1st year: 3 month
intervals
2nd year: 6 month
intervals
Annually from
then on
8 (median) Not reported 2/94 had elevated Tg:
2 true positives
86 true negatives
6 false negatives (2 persistent)
→ 3 of the recurrences were
TgAb+ve, 1 TgAb −ve
Abbreviations: CT computed tomography, DTC differentiated thyroid cancer, FDG PET ﬂuorodeoxyglucose positron emission tomography, MRI magnetic resonance imaging, RIA radioactive
ablation, Tg thyroglobulin, TgAb thyroglobulin antibodies, TSH thyroid stimulating hormone, US ultrasound scan, PE physical examination, WBS 131I whole-body scintigraphy
aDespite analysis of only 94 participants, the initial number of patients described was >100
bMRI was initially performed every 1–2 years and then became less frequent following risk stratiﬁcation
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outcomes, risk of bias and quality of the eligible studies was
planned. Meta-analysis of quantitative outcomes was plan-
ned but was not possible due the lack of data.
The Cochrane Risk of Bias Tool and the
Newcastle–Ottawa Scale (NOS) were selected to assess the
quality of RTCs and observational studies, respectively.
Given the lack of trials addressing the question, single
arm studies were re-evaluated to determine if data on out-
comes, such as survival and quality of life could be col-
lected. Only studies reporting on at least 100 participants
and including a follow-up period of at least 5 years were
included.
This report was written in accordance to the PRISMA
guidance [22]. No external funding was received.
Results
No eligible RCTs or non-randomised two-arm observational
studies that evaluated the effectiveness of routine serum Tg,
neck US or PE in improving the survival or quality of life of
patients with DTC were identiﬁed. The lack of suitable two-
arm studies led to a revision in inclusion criteria and sub-
sequent assessment of three single arm cohort studies that
fulﬁlled the eligibility criteria (Table 3).
Conrad et al. [23] stratiﬁed 343 participants treated with
a near-total thyroidectomy and followed up for an period of
6 (range of 0–20) years. The overall survival was 93% at 20
years and the disease-free survival was 91% and 87% at 10
and 20 years, respectively.
Patients were stratiﬁed using the AMES criteria (age,
metastasis, multifocality, extent of cancer and size) into low
and high risk. 130 low-risk patients were monitored
annually by PE and serum Tg. Six demonstrated elevated
Tg during follow-up and underwent a radioiodine WBS.
Four of six patients showed extra-thyroidal uptake and were
treated for recurrence.
The 213 high-risk patients had a post-operative WBS; 39
with extra-thyroidal uptake had RIA and 135 of 174 patients
without extra-thyroidal uptake who showed ‘non-physio-
logical uptake’ conﬁned to the thyroid bed received RIA.
During the follow-up period, recurrence was diagnosed in
10 of 19 patients with elevated Tg and in eight patients by
palpation. Further details regarding site of recurrence or
treatment for recurrence were not clear. Overall, only two
patients died in the follow-up period from DTC (risk status
not clear); one additional patient died of respiratory failure
after surgery.
Lin et al. [15] allocated 847 patients treated with a total
thyroidectomy and RIA into three groups depending on
post-operative Tg within the ﬁrst month (Group A—
1 month Tg of <1 ng/ml; Group B—Tg ≥ 1 ng/ml and
<10 ng/ml; Group C—≥ 10 ng/ml) (Table 3). These patients
were followed up with 6 monthly WBS, CXR and Tg for a
mean of 3.7 ± 0.2 years in Group A, 6.1 ± 0.2 years in
Group B and 5.4 ± 0.2 years in Group C. At the end of the
study period, 95.8%, 76.4% and 37.1% of patients remained
disease-free (deﬁned as a negative WBS and a Tg of <1 ng/
ml on follow-up) in groups A, B and C, respectively. The 5-
year survival probability was 1.00, 0.992 and 0.963 for
Group A, B and C, respectively. There were no deaths in
Group A (n= 168), six cancer-related deaths in Group B (n
= 331) and 14 cancer-related deaths in Group C (n= 348).
Of the cases in Group C, 133 showed detectable Tg levels
during follow-up.
Phan et al. [24] analysed 94 of 346 patients who were
treated with a near-total thyroidectomy and RIA. These
patients had undetectable Tg before ablation and were
classiﬁed into 30 low-risk patients (<40 years old with no
advanced signs of disease) and 64 high-risk patients (>40
years old with late stage or metastatic cancer). The median
follow-up period was 8 years (range of 1–17). Eight patients
identiﬁed to have either persistent (2) or recurrent disease
(6) at follow up were all high-risk patients. Three recur-
rences were Tg negative/antibody positive and detected by
palpation of enlarged lymph nodes. The fourth patient
identiﬁed by PE was Tg positive/antibody negative. A ris-
ing Tg level identiﬁed the ﬁfth patient with recurrence. The
last patient with recurrence was persistently Tg/antibody
negative and showed multiple lung lesions on chest x-ray.
Discussion
A comprehensive search of three electronic databases did
not identify any RCTs or non-randomised two-arm studies
that evaluated the effectiveness of routine serum Tg, neck
US or PE in patients with DTC. Therefore, there is no clear
high- quality evidence as to whether routine follow-up
improves patients’ quality of life or survival.
It may be that the beneﬁt exists but has not yet been
demonstrated. Waiting for symptomatic recurrence may
increase treatment morbidity and adversely impact on sur-
vival or quality of life. In addition, regular PE by a spe-
cialist face-to-face is ‘reassuring’ to the patient [25] and
may improve mental well-being.
However, there is potential for harm from unnecessary
investigations, treatment-related morbidity, anxiety and/or
distress, and potentially unjustiﬁed costs to the health
service.
Serum Tg has a low positive predictive value (PPV) of
<40%, although it increases with the use of serial mea-
surements [17, 26]. Studies have also shown that frequent
use of US is more likely to identify false-positive ﬁndings
than signiﬁcant disease recurrence [21]. A marked rise in
post-operative US surveillance has been associated with an
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increase in treatment without improvement in disease-
speciﬁc survival [27].
Reoperation is often used as the deﬁnitive treatment for
locally recurrent DTC. However, it is recognised that active
surveillance of small indolent nodules may avoid unneces-
sary interventions [9]. The effect of reoperation on survival
is unknown, but remission rates can be as low as 19% [28]
and morbidity (vocal cord paralysis and hypoparathyroid-
ism) can be signiﬁcant [29].
False positive results and a diagnosis of cancer can also
affect a patient’s mental well-being. Patients concerned
about thyroid cancer recurrence reported low Health-
Related Quality of Life (HRQoL), similar to those who
actually had disease recurrence [30]; suggesting that
reminder of their previous diagnosis may cause psycholo-
gical harm. Patients may also be misled by any apparent
survival beneﬁt (Fig. 2), as a result of ‘lead time bias’ [31].
The ﬁnancial burden of routine surveillance accounts for
over one-third of all expenditure on DTC in the US [32].
This amounts to almost $600 million and is projected to be
as much as $1.4 billion in 2030 [32]. The cost of detection
of recurrent disease in the low-risk group was seven times
greater than the detection of recurrences in the high-risk
group [33]. This is most likely due to the higher frequency
of recurrent disease in the latter cohort. In the absence of a
proven beneﬁt on survival or quality of life, cost-
effectiveness cannot be determined.
Systematic reviews that ﬁnd no eligible studies are
sometimes referred to as ‘empty reviews’ [34]. Postulated
reasons include novel research areas and the use of strict
inclusion criteria. Although these reviews may be con-
sidered to be of limited use [34], they highlight the lack of
evidence on interventions that are currently considered to be
‘standard’ practice [35]. Historically, many practices and
interventions in medicine have been based on anecdote or
on biologically plausible mechanisms and theories in the
absence of empirical data. To ensure continuation of
adherence to an evidence-based medical paradigm, all
interventions in standard practice should be assessed for
risks and beneﬁts from good quality data to ensure that
decisions are made for the beneﬁt of patients.
Amendments to systematic review protocols to include
single arm studies in reviews without RCTs and two-arm
observational studies may be viewed as unconventional.
Furthermore, by revisiting previously excluded studies,
there is potential that the review could be deemed unsys-
tematic and biased [36]. However, this deviation in methods
was necessary to outline what the current state of the evi-
dence is and has been noted on the PROSPERO website.
Without a control arm to make comparisons, only limited
conclusions can be drawn. However, single arm studies
provide a source of valuable data on clinically relevant
outcomes [35]. They also provide baseline parameters on
the basis of which further interventional studies are
designed. Good quality single arm studies may also be
considered sufﬁcient for rare conditions or uncommon
outcomes [37].
The three single arm studies are very heterogenous in
terms of risk classiﬁcation, monitoring protocols, deﬁnition
of recurrent disease and reporting of outcomes. They
however demonstrate low recurrence rates, particularly in
‘low-risk’ patients; irrespective of how risk was deﬁned. A
signiﬁcant proportion of reported recurrences was not
detected by Tg. Importantly, these studies do not demon-
strate that detection and treatment of clinically asympto-
matic recurrence has any inﬂuence on survival or quality of
life.
The beneﬁts of routine surveillance in other areas of
oncology have undergone scrutiny. In breast cancer, rigor-
ous and lifelong follow up has no beneﬁcial effect on sur-
vival and despite increased identiﬁcation of recurrence,
management was not signiﬁcantly affected [38]. In color-
ectal cancer, no statistically signiﬁcant effect on overall
survival, cancer-speciﬁc survival or relapse-free survival
has been found with increase in the intensity of surveillance
[39].
The lack of original data from RCTs and observational
studies is a signiﬁcant limitation of the evidence base.
However, there are practical issues in performing RCTs
including potential ethical concerns regarding equipoise
between intervention and control arms, delayed occurrence
and uncommon nature of relevant end-points (such as
recurrence, thyroid cancer-speciﬁc mortality and overall
mortality); the latter necessitating large sample sizes and
long follow-up periods that are often unrealistic in large
b) Without routine surveillance  
Compleon of 
treatment at 55
Dead at 75 
Recurrence diagnosed because of symptoms 
at 71
Survival after recurrence – 4 years
a) With routine surveillance:  
Compleon of 
treatment at 55 
Dead at 75  
Recurrence diagnosed because of 
roune monitoring at 60
Survival after recurrence – 15 years
Fig. 2 Schematic representation of lead-time bias in cancer recurrence
with (a) or without (b) routine surveillance, adapted from Wegwarth
et al. [31]
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RCTs. Although unlikely, it is possible that eligible studies
in non-English language literature may have been missed. It
is also a limitation that inclusion criteria was revised to
allow the assessment of initially excluded single arm stu-
dies; however, this was deemed necessary in light of the
paucity of higher quality studies.The eligible studies did not
conﬁrm recurrence by histology, which may limit the
validity of their results. These studies have not differ-
entiated between differentiated tumours of the papillary,
follicular and hurthle cell variety. The potential differences
in the biologic behaviour of these tumour types and sub-
types [40, 41] should prompt independent scrutiny of the
utility of follow-up interventions in each of these subtypes;
however, this may be difﬁcult given the uncommon nature
of follicular and hurthle cell types.
In summary, international guidelines and recommended
current practice in the follow-up of patients with DTC are
based on low-quality evidence. There therefore is a need for
re-evaluation of current practice and consideration of the
need for routine follow up, particularly in patients with low-
risk thyroid cancer.
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